ClinicalTrials.gg
RecruitingNCT06660446Updated Feb 19, 2025

Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.

An interventional study of Exercise in Lymphoma, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Biogipuzkoa Health Research Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Lymphoma with a site in Spain — 25 open to participants now, 43 under way, 10 of them phase 3. Lymphoma · Spain.

Planned enrollment
42nd of 134
180 · median 111
Started
2024
with 8 others
No phase
4 of 143
3 open now
Primary completion
2027-03
later than 21 of 42 live
Registered
137th of 143
by date

Among the 143 studies in Lymphoma with a site in Spain, this one is the 42nd largest by planned enrollment of the 134 interventional ones that give a count, is one of 9 that started in 2024, is one of 4 with no phase, reaches primary completion later than 21 of the 42 other live ones, and was the 137th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

25 of the 143 studies in Lymphoma with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Lymphoma with a site in Spain, or all of them as a file.
02

Study summary

In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. //2.Reduce fatigue//3.Reduce frailty

There is an association between some biological biomarkers with physical capacity and frailty.

Read the detailed description

In this study, the effectiveness of an individualized adjuvant exercise program will be analyzed in a homogeneous population of people diagnosed with lymphoma in active treatment. Taking into account the limited scientific evidence that currently exists in people affected by lymphoma and active treatment, the study could be of great relevance when it comes to providing scientific evidence in this very little field studied. The study will try to respond to the evident need to focus the research area on supervised exercise in people with lymphoma in a way innovative, with the aim of generating new hypotheses that overcome existing limitations and facilitate the introduction of this type of interventions into the health system. The present study will also analyze the effect of exercise from a gender perspective, an aspect not systematically studied until now, providing a new vision on the baseline differences and after intervention of a program based on of sex.

The study will include adults with lymphoma with special focus on the subanalysis of the group of patients equal or more than 70 years old. The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new exercise project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic. 30 people with lymphoma and treatment have been included in the Onkofrail study asset. The preliminary results of said pilot study have been used for the design of this new study, making adaptations, both in the recruitment time, as well as inclusion and exclusion criteria, which guarantee and optimize the correct research development.

Main objective:

The main objective is to assess whether a supervised (2 days/week) combined (resistance+aerobic interval training) exercise intervention, plus 2 days/week unsupervised for 20 weeks improves cardiorespiratory fitness (CRF) in people diagnosed with lymphoma undergoing chemotherapy, compared to a control group receiving only general recommendations.

Secondary objectives:

  1. To estimate cardiorespiratory capacity (VO2peak) through a field test Modified Shuttle Walking Test (MSWT) and other covariates related to body composition, heart rate, among others. Validation of the predictive model.
  2. To characterise and define the profile of the population diagnosed with lymphoma at the physical, emotional, and biochemical (biomarker) and immune system level prior to an intervention with exercise.
  3. To investigate whether the implementation of an exercise programme adjuvant to immunochemotherapy treatment modifies fatigue, adherence (actual dose-intensity), and toxicity related to clinical treatment.
  4. To analyse whether the intervention with exercise is effective in increasing strength levels, improving quality of life and sleep.
  5. To clarify whether there are sex differences in the efficacy of the exercise programme adjuvant to immunochemotherapy treatment.
  6. To analyse the benefit of adding exercise programmes in different subgroups of people with lymphoma, with a special focus on the group of patients aged ≥70 years, with the aim of maximising the cost-effectiveness of implementation in the care routine in all patients.
  7. To analyse the degree of adherence to the programme: degree of attendance at planned sessions and percentage of participants who complete the post-intervention evaluation.
  8. To report the degree of satisfaction by people affected by lymphoma, as reported in an interview.
03

Conditions studied

  • Lymphoma

Keywords

  • Lymphoma
  • Physical Exercise
  • Fatigue
  • Cardiorespiratory capacity
  • Life Quality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥18 years old.
  • Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy.
  • Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions.
  • Have a mobile phone to be able to contact the person and download the physical activity level app.
  • performance status (ECOG) ≤2.
  • \>12 months.
  • Availability and desire to participate throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • Have a to moderate-high intensity exercise.
  • Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise.
  • Have plans to be outside city more than two weeks.
  • People who are already physically active (that comply with the recommendations of WHO: \> 150 minutes of exercise moderate/weekly, plus training force two days/week).
  • Treatment based only with immunotherapy.
  • Central nervous system involvement due to lymphoma.
  • Have any important history that limit the capacity of the patient to participate in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • No intervention
    Control Group

    The control group will receive the usual care and indications.

  • Experimental
    Intervention Group

    The interventional group will add a exercise program.

    Other: Exercise

Interventions

  • OtherExercise

    The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness (CRF)

    Measured by peak oxygen uptake (VO2peak) before starting chemotherapy treatment and after 20 weeks of intervention, using the cardiorespiratory exercise test.

    Time frame: 20 weeks

Secondary outcomes

  1. Sociodemographic, etiological and clinical health variables (A)

    Recruitment Center (Donostia University Hospital, Galdakao University Hospital , Alava University Hospital)

    Time frame: 20 weeks

  2. Sociodemographic, etiological and clinical health variables (B)

    Birthdate.

    Time frame: 20 weeks

  3. Sociodemographic, etiological and clinical health variables (C)

    Biological sex (man, woman, I prefer not to answer)

    Time frame: 20 weeks

  4. Sociodemographic, etiological and clinical health variables (D)

    Gender (man, woman, non-binary or I prefer not to answer)

    Time frame: 20 weeks

  5. Sociodemographic, etiological and clinical health variables (E)

    Educational level (no studies, elementary, high school, vocational training, university, I prefer not to answer, others)

    Time frame: 20 weeks

  6. Sociodemographic, etiological and clinical health variables (F)

    Home composition (single person, lives with couple, lives with family, institutionalized, I prefer not to answer, others)

    Time frame: 20 weeks

  7. Functionality and fragility variables at times T0, T1 and T2 (A.1.)

    Muscle power and fragility --\> SIT - TO STAND (STS) POWER: time to repeat the action 5 (sec)

    Time frame: 20 weeks

  8. Functionality and fragility variables at times T0, T1 and T2 (A.2.)

    Muscle power and fragility --\> FRAILTY TRAIT TEST SCALE (FTS-5): BMI (kg/m)2; running time (sec); grip strength (kg); Progressive Romberg Test (positive/negative).

    Time frame: 20 weeks

  9. Functionality and fragility variables at times T0, T1 and T2 (B.1.)

    G8 Scale (0-17 pts)

    Time frame: 20 weeks

  10. Functionality and fragility variables at times T0, T1 and T2 (B.2.)

    Fried Frailty Phenotype (0-5 pts)

    Time frame: 20 weeks

  11. Functionality and fragility variables at times T0, T1 and T2 (C)

    Physical Condition: Modified Shuttle Walking Field Test (meters)

    Time frame: 20 weeks

  12. Functionality and fragility variables at times T0, T1 and T2 (D)

    UPPER BODY MUSCLE STRENGTH (HANGRIP) (Newton)

    Time frame: 20 weeks

  13. Functionality and fragility variables at times T0, T1 and T2 (E)

    Body composition --\> Height (cm); Weight (kg); Waist circumference (cm); hip circumference (cm); body mass index (kg/m2); fat free mass (kg and %); fat mass (kg and %); total body water (kg and %); phase angle (º); systolic blood pressure (mmHG); diastolic blood presure (mmHg); resistance (Ω); reactance (Ω).

    Time frame: 20 weeks

  14. Functionality and fragility variables at times T0, T1 and T2 (F)

    Physical activity level --\> Global Questionnaire on Physical Activity (GPAQ)

    Time frame: 20 weeks

  15. Functionality and fragility variables at times T0, T1 and T2 (G)

    Sleep Quality --\> Epworth Sleepiness Scale (ESS EPWORTH) (0-24 pts)

    Time frame: 20 weeks

  16. Functionality and fragility variables at times T0, T1 and T2 (H)

    Acelerometry (h/d)

    Time frame: 20 weeks

  17. Patient Reported Results (A)

    Quality of Life Questionnaire --\> Hematological Malignancy - Patient Reported Outcome (HM-PRO) at times T0, T1 and T2 (Nothing, mild and serious)

    Time frame: 20 weeks

  18. 3. Patient-reported results (PRO):

    EORTC QLQ - FA13

    Time frame: 20 weeks

  19. Biomarkers

    Inflammation (pg/ml or ng/ml), Hematological (pg/ml or ng/ml), Endocrine Nutritional (pg/ml or ng/ml), Immunosenescence (pg/ml or ng/ml),

    Time frame: 20 weeks

  20. Variables of Geriatric Assessment (VGA) comprehensive in patients (A)

    Gijon Scale (3-15 pts)

    Time frame: 20 weeks

  21. Variables of Geriatric Assessment (VGA) comprehensive in patients (B)

    Basic Activity of Dialy Living (BADL) - Barthel Scale (0-10 pts)

    Time frame: 20 weeks

  22. Variables of Geriatric Assessment (VGA) comprehensive in patients (C)

    Instrumental Activity of Dialy Livings (IADL) - Lawton Scale (0-8 pts)

    Time frame: 20 weeks

  23. Variables of Geriatric Assessment (VGA) comprehensive in patients (D)

    Cognitive Function - Pfeiffer Test (0-10 pts)

    Time frame: 20 weeks

  24. Variables of Geriatric Assessment (VGA) comprehensive in patients (E)

    Nutritional Status - Mini Nutritional Assessment Short-form (MNA.SFI) (0-14 pts)

    Time frame: 20 weeks

  25. Variables of Geriatric Assessment (VGA) comprehensive in patients (F)

    Polypharmacy (number of chronica drug consumed by the participant)

    Time frame: 20 weeks

  26. Variables of Geriatric Assessment (VGA) comprehensive in patients (G)

    Geriatric Syndromes - Immobility and pressure ulcers (Yes/No); instability and falls (Yes/No); urinary and faecal incontinence (Yes/No); dementia and acute confusional syndrome ( Yes//No); malnutrition (Yes/No); alterations in sight and hearing (Yes/No);constipation, faecal impaction (Yes/No);depression/insomnia (Yes/No)

    Time frame: 20 weeks

  27. Variables of Geriatric Assessment (VGA) comprehensive in patients (H)

    Pain - Visual Analogue Scale (VAS) (0-10 pts)

    Time frame: 20 weeks

  28. Variables of Geriatric Assessment (VGA) comprehensive in patients (I)

    Emotional Distress - Stress Thermometer (0-10 pts)

    Time frame: 20 weeks

  29. Treatment data and results after the intervention (T2) (A)

    Treatment Suspension (Yes/No)

    Time frame: 20 weeks

  30. Treatment data and results after the intervention (T2) (B)

    Dose Reduction (Yes/No)

    Time frame: 20 weeks

  31. Treatment data and results after the intervention (T2) (C)

    Treatment percentage completed (%)

    Time frame: 20 weeks

  32. Treatment data and results after the intervention (T2) (D)

    Treatment Completion (Yes/No)

    Time frame: 20 weeks

  33. Assessment of the intervention at T2 (A)

    Adverse events associated with intervention (Number of adverse events)

    Time frame: 20 weeks

  34. Assessment of the intervention at T2 (B)

    Satisfaction with the intervention (Yes/No)

    Time frame: 20 weeks

  35. Assessment of the intervention at T2 (C)

    Adherence to the intervention (Yes/No)

    Time frame: 20 weeks

07

Study locations

1 of 3 sites recruiting
  • Hospital Universitario Araba (HUA)
    Vitoria - Gateiz, Araba 01009, Spain
    Not yet recruiting
  • Hospital Universitario Galdakao (HUG)
    Galdakao, Bizkaia 48960, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Universitario Donostia (HUD)
    San Sebastián, Guipuzcoa 20014, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 29 months is below that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 28, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06660446
Lead sponsor
Biogipuzkoa Health Research Institute
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Oct 8, 2024
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Clinical Research Platform - Health Research Institut Biogipuzkoa
Contact
OSID.INVESTCLINICA@osakidetza.eus
+34943006140
Izaskun Zeberio Etxetxipia
principal investigator · Hospital Donostia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion